+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Scandinavia Pharmaceuticals Market Summary, Competitive Analysis and Forecast to 2027

  • PDF Icon

    Report

  • 47 Pages
  • October 2023
  • Region: Denmark, Norway, Sweden
  • MarketLine
  • ID: 5782107
Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2017-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

  • The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
  • The Scandinavian pharmaceuticals market had total revenues of $17.1 billion in 2022, representing a compound annual growth rate (CAGR) of 3.4% between 2017 and 2022.
  • 0
  • Sweden acquired a 38% share of the Scandinavian pharmaceuticals market in 2022. The Nordics are a significant hub for pharmaceutical innovation and production, with Finland having one of Europe's fastest-aging populations. With over 23% of people aged 65 or over, the region has a high life expectancy at birth. Lifestyle-related diseases like diabetes and obesity are driving growth in the pharmaceutical markets, particularly cardiovascular ones.

Scope

  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the pharmaceuticals market in Scandinavia
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Scandinavia
  • Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia pharmaceuticals market with five year forecasts by both value and volume

Reasons to Buy

  • What was the size of the Scandinavia pharmaceuticals market by value in 2022?
  • What will be the size of the Scandinavia pharmaceuticals market in 2027?
  • What factors are affecting the strength of competition in the Scandinavia pharmaceuticals market?
  • How has the market performed over the last five years?
  • What are the main segments that make up Scandinavia's pharmaceuticals market?

Table of Contents

1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market rivalry
1.5. Competitive landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What strategies do leading players follow?
7.3. What are the most recent market developments?
8 Company Profiles
8.1. Novartis AG
8.2. Sanofi SA
8.3. Pfizer Inc.
8.4. F. Hoffmann-La Roche Ltd
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related research
10.4. About the Publisher
List of Tables
Table 1: Scandinavia pharmaceuticals market value: $ billion, 2017-22
Table 2: Scandinavia pharmaceuticals market geography segmentation: $ billion, 2022
Table 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2022-27
Table 4: Novartis AG: key facts
Table 5: Novartis AG: Annual Financial Ratios
Table 6: Novartis AG: Key Employees
Table 7: Novartis AG: Key Employees Continued
Table 8: Sanofi SA: key facts
Table 9: Sanofi SA: Annual Financial Ratios
Table 10: Sanofi SA: Key Employees
Table 11: Sanofi SA: Key Employees Continued
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: Annual Financial Ratios
Table 14: Pfizer Inc.: Key Employees
Table 15: Pfizer Inc.: Key Employees Continued
Table 16: F. Hoffmann-La Roche Ltd: key facts
Table 17: F. Hoffmann-La Roche Ltd: Annual Financial Ratios
Table 18: F. Hoffmann-La Roche Ltd: Key Employees
Table 19: Scandinavia exchange rate, 2018-22
List of Figures
Figure 1: Scandinavia pharmaceuticals market value: $ billion, 2017-22
Figure 2: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2022-27
Figure 4: Forces driving competition in the pharmaceuticals market in Scandinavia, 2022
Figure 5: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2022
Figure 6: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2022
Figure 7: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2022
Figure 8: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2022
Figure 9: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2022

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Novartis AG
  • Sanofi SA
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd